OTC Markets
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.01
Exchange OTC Markets
Shares Outstanding 10.79B
Market Cap 3.20K
Div & Yield N.A. (N.A)

Advanced Life Sciences To Explore Strategic Alternatives To Maximize Shareholder Value

Company Enters into Loan Amendment with Bank to Remove Default

Advanced Life Sciences Submits Full Proposal To NIAID For Development Of Intravenous Formulation Of Restanza As A Biodefense Countermeasure

Company Requests $38 million for Development of IV Formulation of Restanza to Treat CABP and as a Therapeutic Treatment for Anthrax, Plague and Tularemia

Advanced Life Sciences Participates In Key Infectious Disease Conference

Company exhibits at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Advanced Life Sciences' Journal Publication Highlights Powerful Chemistry Platform

-Article presents data on triterpenoids showing potent anticancer activity-

Advanced Life Sciences Sees Funding Opportunity For Restanza In New HHS Medical Countermeasure Report

Restanza as broad biodefense countermeasure and pneumonia treatment fits profile of novel drug to combat public health threats

Advanced Life Sciences To Participate In Key Infectious Disease Conference

Company presenting data and exhibiting at 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)

Advanced Life Sciences Achieves Special Protocol Assessment Agreement With FDA For Restanza In Pneumonia

First-of-its-Kind Superiority Trial Compares Restanza to Standard of Care in Antibiotic-Resistant Pneumonia Population

Advanced Life Sciences Featured As Special Stock Pick By KonLin Investment Letter

Independent Financial Newsletter Puts Stock Target at $1.00

Advanced Life Sciences Expands Antibiotic Pipeline

Company Partners with The University of British Columbia to Acquire and Develop Novel Antibiotics Against Gram-Negative Pathogens